Renovaro Biosciences Inc. (RENB)
0.81
-0.09 (-10.01%)
At close: Jan 14, 2025, 3:59 PM
0.78
-4.20%
Pre-market Jan 15, 2025, 08:12 AM EST
undefined% (undefined)
| Bid | 0.78 |
| Market Cap | 129.24M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.98 |
| PE Ratio (ttm) | -0.83 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.84 |
| Volume | 313,335 |
| Avg. Volume (20D) | 1,083,957 |
| Open | 0.94 |
| Previous Close | 0.90 |
| Day's Range | 0.79 - 0.94 |
| 52-Week Range | 0.40 - 5.25 |
| Beta | undefined |
About RENB
Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatme...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 7, 2018
Employees 25
Stock Exchange NASDAQ
Ticker Symbol RENB
Website https://www.renovarobio.com
3 months ago ·
Source
+32.01%
Renovaro shares are trading higher. The company ap...
Unlock content with
Pro Subscription
11 months ago ·
Source
-42.86%
Renovaro Biosciences shares are trading lower after Hindenburg Research issued a report on the company and said it has taken a short position in the stock.
